YIH
RCKT icon

Y-Intercept (HK)’s Rocket Pharmaceuticals RCKT Stock Holding History

Y-Intercept (HK)’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,089
Closed -$280K – 1495
2023
Q2 		$280K Buy
+14,089
New +$285K 0.03% 797

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Y-Intercept (HK)'s RCKT Position: Q3 2023 in Review

Y-Intercept (HK) sold out of Rocket Pharmaceuticals (RCKT) in Q3 2023, closing a stake of 14,089 shares — an estimated $280K sold.

Y-Intercept (HK) first reported a position in RCKT in Q2 2023 and held it in 1 quarter. The position peaked at $280K in Q2 2023. 175 funds tracked by Wall St. Rank hold RCKT as of Q3 2023.

  • Y-Intercept (HK) reported no remaining Rocket Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Y-Intercept (HK) sold 14,089 Rocket Pharmaceuticals shares in Q3 2023, an estimated $280K.
  • Y-Intercept (HK) first reported a position in Rocket Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Y-Intercept (HK)'s Rocket Pharmaceuticals position peaked at $280K in Q2 2023.
  • 175 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2023.

Based on Y-Intercept (HK)'s 13F filing for Q3 2023, filed 14 Nov 2023.